Exelixis dips after combo leads to disappointing ORRs
Exelixis Inc. (NASDAQ:EXEL) fell $2.13 (14%) to $13.35 on Wednesday after new data showed a combination of the company's Cabometyx cabozantinib plus PD-1 inhibitor Opdivo nivolumab led to an overall response rate (ORR) in genitourinary cancer that was lower than ORRs produced by other combinations of immuno-oncology agents and targeted therapies. The data were in abstracts released ahead of next month's European Society for Medical Oncology (ESMO) meeting in Copenhagen.
In a Phase I study, Cabometyx plus Opdivo led to an ORR of 33% in 18 evaluable patients with metastatic genitourinary tumors. There was one complete response in a patient with bladder squamous cell carcinoma, and five partial responses in patients with bladder, kidney, urethral or prostate cancers. ...